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Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common inherited human enzyme defect.
This deficiency provides some protection from clinical malaria, but it can also cause haemolysis after administration of drugs
with oxidant properties.
Methods: The safety of chlorproguanil-dapsone+artesunate (CD+A) and amodiaquine+sulphadoxine-pyrimethamine
(AQ+SP) for the treatment of uncomplicated P. falciparum malaria was evaluated according to G6PD deficiency in a
secondary analysis of an open-label, randomized clinical trial [1]. 702 children, treated with CD+A or AQ+SP and followed for
28 days after treatment were genotyped for G6PD A- deficiency.
Findings: In the first 4 days following CD+A treatment, mean haematocrit declined on average 1.94% (95% CI 1.54 to 2.33)
and 1.05% per day (95% CI 0.95 to 1.15) respectively in patients with G6PD deficiency and normal patients; a mean
reduction of 1.3% per day was observed among patients who received AQ+SP regardless of G6PD status (95% CI 1.25 to
1.45). Patients with G6PD deficiency recipients of CD+A had significantly lower haematocrit than the other groups until day
7 (p = 0.04). In total, 10 patients had severe post-treatment haemolysis requiring blood transfusion. Patients with G6PD
deficiency showed a higher risk of severe anaemia following treatment with CD+A (RR = 10.2; 95% CI 1.8 to 59.3) or AQ+SP
(RR = 5.6; 95% CI 1.0 to 32.7).
Conclusions: CD+A showed a poor safety profile in individuals with G6PD deficiency most likely as a result of dapsone
induced haemolysis. Screening for G6PD deficiency before drug administration of potentially pro-oxidants drugs, like
dapsone-containing combinations, although seldom available, is necessary.
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Introduction
Glucose-6-phosphate dehydrogenase (G6PD) plays a critical role
in protecting red cells from oxidant haemolysis. G6PD allows
regeneration of NADPH, which is essential for glutathione recycling
and protection against oxidative damage. G6PD deficiency is the
most common inherited human enzyme defect, present in more than
400 million people worldwide. The gene encoding G6PD is located
on the X chromosome; G6PD-deficient hemizygous males and
homozygous females are vulnerable to oxidant haemolysis, whereas
heterozygous females have variable (milder) deficiency determined
by the degree of X-chromosomal inactivation.
There are numerous polymorphisms of the G6PD gene.
Approximately 200 variant alleles have been described and 140
mutations, or combination of mutations, have been identified [2].
The high prevalence of G6PD deficiency in the tropics and
Mediterranean areas is attributed to a protective effect against
clinical P. falciparummalaria [3,4]. Despite extensive heterogeneity, a
single molecular variant, G6PD A- predominates in sub-Saharan
Africa where it affects 15 to 20% of the African population, although
there are marked differences between regions within the continent
[5]. The A- variant differs from the normal G6PD B allele by two
missense mutations, an A to G transition at position 376, encoding
the so called ‘‘B’’ to ‘‘A’’ change (Asn126Asp), and a G to A
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transition at position 202, encoding the ‘‘A-’’ change (Val68Met).
This additional mutation differentiates the ‘‘A-’’ allele with 12%
enzymatic activity, from the ‘‘A’’ allele with 85% activity [6].
Acute haemolytic anaemia is the most frequent clinical
manifestation associated with G6PD deficiency. This can be
precipitated by foods or drugs with oxidant properties. The degree
of drug-induced G6PD deficiency related haemolysis depends on a
number of factors including the G6PD variant, the drug and
dosage, and poorly characterised disease factors. Sulphonamides
and sulphones are still widely used in tropical countries, and may
cause haemolysis in patients with G6PD deficiency. Dapsone is
used as a treatment of leprosy, some skin conditions, and more
recently Pneumocystic carinii pneumonia [7]. It is used in
combination with pyrimethamine, proguanil and chlorproguanil
for malaria prophylaxis and malaria treatment. The most frequent
adverse effects of dapsone are haematological. These include
methaemoglobinaemia, haemolysis and anaemia, and less com-
monly agranulocytosis and idiosyncratic reactions (known as
dapsone hypersensitivity syndrome). Patients with genetic defi-
ciencies of enzymes involved in oxidant defences, such as G6PD or
glutathione reductase, are more susceptible to haemolysis [7,8].
In 2005–2006 an open label, randomised clinical trial was
carried out in Rwanda to evaluate the safety and efficacy of
artesunate+chlorproguanil-dapsone and amodiaquine+sulphadox-
ine-pyrimethamine for the treatment of uncomplicated P.
falciparum malaria in children [1].
We evaluated the safety profiles of these two antimalarial
treatments according to G6PD deficiency.
Methods
Study design
The drug trial has been described in detail elsewhere [1]. Briefly,
we tested efficacy and safety of chlorproguanil-dapsone co-
administered with artesunate (CD+A), compared to amodiaquine
combined with sulphadoxine-pyrimethamine (AQ+SP), for the
treatment of uncomplicated P. falciparum malaria in Rwanda. The
trial was open label; 800 patients, aged 6–59 months, with
uncomplicated malaria were randomised to receive AQ+SP (400)
or CD+A (400). Patients were hospitalized for 4 days, so that
appropriate management, including blood transfusion, could be
performed and followed–up weekly until day 28 after treatment.
Clinical and parasitological outcomes were recorded according to
WHO guidelines [9]. Only patients with Packed Cell Volumes
(PCV; haematocrit) $21% (corresponding to haemoglobin 7 g/dL)
were included in the trial [10]. PCV was measured by microhae-
matocrit centrifugation each day during treatment and at each visit
during follow-up. If necessary the measure was repeated twice a day.
Blood was collected on Whatman filter paper for genotyping.
The initial protocol of the clinical study included an arm with
CD alone, but this arm was discontinued because of the
remarkably high number of failures observed at an early stage
and thereafter patients were allocated to CD+A or AQ+SP only.
Drug administration
CD+A: CD was administered orally at doses of 2.0 mg/kg
chlorproguanil and 2.5 mg/kg dapsone once daily for 3 days using
commercial LapdapH paediatric tablets containing 15 mg of chlor-
proguanil hydrochloride and 18.75 mg of dapsone (GlaxoSmithK-
line, Brentford, UK) together with artesunate 4 mg/kg/day for 3
days using 50 mg tablets (Sanofi-Aventis, Gentilly Cedex, France).
AQ+SP: AQ was administered orally at a dose of 10 mg/kg
daily for 3 days and SP was co-administered at a dose of 25 mg/kg
sulphadoxine plus 1.25 mg/kg pyrimethamine the first day.
AQ+SP and artesunate were both provided by Sanofi-Aventis
(Gentilly-Cedex, France).
Definitions
A patient was defined as an Early Treatment Failure (ETF) if she/
he had any of the following: i) danger signs or severe malaria on
days 1, 2 or 3 with parasitaemia; ii) parasite density at day 2
greater than at day 0; iii) parasitaemia on day 3 with axillary
temperature$37.5uC and iv) parasite density at day 3 equal to or
greater than 25% of that at day 0 [9]. A Serious Adverse Event was
defined as any untoward medical occurrence that at any dose
results in death, requires inpatient hospitalisation or prolongation
of existing hospitalisation, results in persistent or significant
disability/incapacity or is life-threatening.
Ethics
The clinical protocol of the original study was approved by the
Ministry of Health of Rwanda, the ethical Committees of the London
School of Hygiene and Tropical Medicine, London, UK, and the
Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium. As
soon as the analyses of the blood samples were available, the families
of children with G6PD deficiency were traced and informed by a
medical doctor with a health worker. An explanatory health-card was
given to the families which could be presented to hospital.
G6PD (A-) genotyping
DNA extraction from Whatman filter papers was performed
using standard Chelex method [11]. The G6PD A- allele
(202GRA) has been characterized using the following primers:
FOR 59- CTG GCC AAG AAG AAG ATC TAC CC-39 and
REV 59- GAG AAA ACG CAG CAG AGC ACA G 39. DNA
(50–100 ng) was amplified in a total reaction volume of 30 ml
consisting of reaction buffer, 2 mM MgCl2, 0.1 mmol of each
primer, 0.1 mM dNTPs each and 1 U of BioTaq DNA
polymerase (Bioline). A touchdown program was used to prevent
non-specific amplification; an initial denaturation step at 95uC for
5 min was followed by 14 cycles at 95uC for 40 s, 68.5uC for 40 s,
and at 72uC for 40 s, with annealing temperature decreasing
0.5uC per cycle; the programme was completed by 23 additional
cycles with annealing temperature 61uC and a final extension step
at 72uC for 10 min. Amplified fragments were digested with NlaIII
(NEBiolabs) restriction enzyme at 37uC for 4 hours and analysed
with 2.5% MetaPhor (Cambrex) gel electrophoresis.
Statistical analysis
Data were double-entered using Microsoft Access 2003 and
validated using Epi Info 3.3.2 (CDC, Atlanta, GA, USA). All
analyses were performed using STATA statistical analysis software
package version 10.0 (StataCorp., College Station, TX, USA).
Patients were categorised into four groups for comparison:
AQ+SP G6PD (B) (without G6PD deficiency), AQ+SP G6PD (A-)
(with G6PD deficiency), CD+A G6PD (B) (without G6PD
deficiency) and CD+A G6PD (A-) (with G6PD deficiency).
Homozygous females and hemizygous males were considered as
patients with G6PD deficiency. We also conducted a sensitivity
analysis including the heterozygous G6PD females in the group of
patients with G6PD deficiency.
Continuous data with a normal distribution were compared using
ANOVA and the non-parametric Kruskal-Wallis test was used to
analyse continuous data with a skewed distribution. Proportions
were compared using chi-squared or Fisher’s exact test.
The overall fractional reduction in haematocrit was defined as
the difference between the patient’s lowest level of haematocrit
G6PD and Antimalarial Drugs
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and that at baseline (i.e., pre-treatment) divided by the
haematocrit at baseline. The fractional reduction from day 0 to
day 3 was calculated in a similar manner.
The differences in the rate of decline in haematocrit levels from
day 0 to day 3 were assessed in a separate model from the rate of
recovery from day 7 to day 28. For each model, a regression line
was fit for each patient and differences between groups as well as
within group variation were adjusted for using random effects. The
models were also adjusted for parasitaemia and temperature at
presentation. The Odds Ratios (OR) and Risk Ratios (RR) were
calculated with 95% Confidence Intervals (95% CI) using a 2-
sided Fisher’s exact test.
Results
In the original study 792 children were studied of whom 702
were successfully genotyped for the G6PD variant A- (at position
202). For the remaining patients (10.3% in the AQ+SP arm and
14.2% in the CD+A arm; p= 0.1) samples were not received or
DNA extraction was not successful. The total G6PD allelic
frequency in the study population was 9.6% in the males (34
hemizygous subjects and 320 normal subjects) and 7.5% in the
females (44 heterozygous and 4 homozygous females and 300
normal subjects), p = 0.3 (Table 1). The PCV at baseline (pre-
treatment) was comparable between G6PD hemizygous and
homozygous children (median PCV=32%, range 23–39), G6PD
heterozygous children (median PCV=33%, range 25–38) and
normal children (median PCV=33%, range 21–46). Demograph-
ic and clinical characteristics pre-treatment were also similar in the
four defined groups: AQ+SP G6PD (B), AQ+SP G6PD (A-),
CD+A G6PD (B) and CD+A G6PD (A-) (all p.0.1; Table 2).
Haematocrit changes in relation to drug treatment and
G6PD genotype with the heterozygous females
considered as normal subjects
Univariate analysis. Between day 1 and 3 the mean PCV
decreased in all four groups. After day 7, mean PCV increased
steadily in all groups (Figure 1). The largest overall mean (SD)
fractional reduction was observed in the CD+A G6PD (A-) group
(Table 3). The proportion of patients whose PCV fell below 20 and
25% was also significantly higher in the CD+A G6PD (A-) group
when compared with all other groups; when all other patients were
combined into one group, the odds of a severe reduction in the
haematocrit (defined as the proportion of patients whose PCV fell
below 20%) was 9 times more likely to occur in patients with
G6PD deficiency recipients of CD+A (OR=9.2, 95% CI 2.8 to
30.2, p,0.001).
The mean fractional reduction (SD) from day 0 to day 3 was
also highest in the CD+A G6PD (A-) group: 19.8% (12.5)
compared with 12.0% (10.6) in the AQ+SP G6PD (B) group,
11.6% (9.34) in the AQ+SP G6PD (A-) group and 10.0% (9.26) in
the CD+A G6PD (B) group (p,0.001).
Multivariate analysis. Between day 0 and day 3 compared
with patients in the AQ+SP G6PD (B) group, those in the CD+A
G6PD (A-) group had a significantly higher rate of decline in PCV,
after adjustment for (log) parasitaemia and temperature at day 0
(p = 0.04); whereas PCV levels declined at the same rate in the
AQ+SP G6PD (A-) group and CD+A G6PD (B) group when
compared with patients in the AQ+SP G6PD (B) group (p= 0.79
and p= 0.56, respectively). In the first 4 days, haematocrit
declined, on average, 1.3% per day for all patients who received
AQ+SP treatment, regardless of G6PD status (95% CI 1.25 to
1.45). For patients in the CD+A G6PD (B) group, haematocrit
levels declined, on average, 1.05% per day (95% CI 0.95 to 1.15)
Table 1. G6PD (A-) frequency according to sex and treatment
(AQ+SP: amodiaquine+sulphadoxine-pyrimethamine; CD+A
chlorproguanil-dapsone+artesunate).
CD+A AQ+SP Total
Boys
Hemizygous 18 16 34
Normal 162 158 320
Total 180 174 354
G6PD (A-) % frequency 10.0 9.2 9.6
Girls
Heterozygous 23 21 44
Homozygous 3 1 4
Normal 137 163 300
Total 163 185 348
G6PD (A-) % frequency a 8.9 6.22 7.5
aComparison between boys and girls p = 0.3.
doi:10.1371/journal.pone.0004031.t001
Table 2. Demographic and clinical characteristics of children at enrolment according to treatment (AQ+SP:
amodiaquine+sulphadoxine-pyrimethamine; CD+A chlorproguanil-dapsone+artesunate) and presence of the G6PD (A-) deficiency
allele (hemizygous males, homozygous and heterozygous females).
Demography and clinical characteristics AQ+SP G6PD(B) AQ+SP G6PD(A-) CD+A G6PD(B) CD+A G6PD(A-)
Female:Male 163:158 22:16 137:162 26:18
Mean age in months (SD) 28.3 (14.1) 31.9 (14.3) 29.0 (14.9) 30.1 (14.0)
Mean weight in kg (SD) 11.0 (2.5) 11.8 (2.6) 11.2 (2.4) 11.0 ( 2.2)
Mean temperature uC (SD) 38.5 (1.3) 38.4 (1.5) 38.5 (1.3) 38.9 (1.2)
Axillary temperature $37.5uC (%) 230/321 (71.7) 26/38 (68.4) 221/299 (73.9) 35/44 (79.6)
Geometric mean asexual P.falciparum/mL (95%CI) 22262.8 (19697.6–25162.0) 28158.0 (19348.4–40978.6) 22731.5 (19860.0–26018.2) 26808.5 (18950.4–37925.0)
Median PCV (range) 33 (22–43) 34 (23–39) 33 (21–46) 31 (23–38)
Splenomegaly (%) 2/321 (0.6) 0/38 4/295 (1.34) 0/44
Hepatomegaly (%) 0 0 0 0
doi:10.1371/journal.pone.0004031.t002
G6PD and Antimalarial Drugs
PLoS ONE | www.plosone.org 3 December 2008 | Volume 3 | Issue 12 | e4031
whereas in the CD+A G6PD (A-) group, the mean haematocrit
decline was greater, 1.94% per day (95% CI 1.54 to 2.33).
From day seven, the haematocrit increased steadily in all
groups. The rate of increase per day was similar (0.24%) for all
patients treated with AQ+SP regardless of G6PD status (95% CI
0.22 to 0.25) and after adjustment for (log) parasitaemia at day 0.
Haematocrit levels for patients in the CD+A (B) group increased
0.27% per day (95% CI 0.26 to 0.29) and 0.35% per day (95% CI
0.28 to 0.42) in patients in the CD+A G6PD (A-) group.
Sensitivity analysis with heterozygous females
considered as deficient subject
When we included the heterozygous females in the deficient
groups the findings remained the same. At day one after treatment
the haematocrit was lower than at baseline, but still comparable in
the four groups (p = 0.12); after day 1 the reduction was again
greater in patients in the CD+A G6PD (A-) group, which had a
significantly lower mean PCV at days 2 and 3 (p= 0.01 and
p,0.001 respectively). After day 7, results were identical.
In the multivariate analysis, those in the CD+A G6PD (A-)
group had a significantly higher rate of decline in PCV compared
with patients in the AQ+SP G6PD (B) group, (p = 0.004) after
adjustment for (log) parasitaemia and temperature day 0; whereas
PCV levels in the AQ+SP G6PD (A-) group and CD+A G6PD (B)
group declined at the same rate when compared with patients in
the AQ+SP normal group (p = 0.99 and p= 0.34 respectively).
From day 7, results were also comparable: the rate of increase per
day was similar for all patients treated with AQ+SP regardless of
G6PD status (p = 0.28) and both CD+A G6PD (A-) and G6PD (B)
patients had a higher increase compared to AQ+SP G6PD (B)
patients (p,0.001) after adjustment for (log) parasitaemia at
baseline.
Blood transfusions
During the study 12 patients had a rapid fall of the haematocrit
with other danger signs or severe malaria on days 1, 2 or 3 with
parasitaemia (general danger signs of severe illness were defined as:
inability to drink or breastfeed; vomiting; recent history of
convulsions; lethargy or unconsciousness and inability to sit or
stand up). Nine of those received a blood transfusion within four
days of recruitment along with parenteral quinine and other
supportive therapies (table 4). Four patients (3 G6PD hemizygous
males and 1 non-deficient female) were treated with CD+A and 5
other patients (1 homozygous and 1 heterozygous female and 3
normal subjects males) that received a blood transfusion were
treated with AQ+SP. Another patient, G6PD (B) treated with
CD+A, required a blood transfusion at day 14. He was diagnosed
with a concomitant disease and treated accordingly.
Those cases were classified as Early Treatment Failures (apart
from the patient who developed severe anaemia at day 14) with
possible Serious Adverse Events as clinically it was not possible to
distinguish whether the haemolysis was a consequence of the
malaria infection only or also drug related. It is possible that the
poor efficacy of AQ+SP, which resulted in a higher number of
Figure 1. Mean PCV according to treatment group (AQ+SP: amodiaquine+sulphadoxine-pyrimethamine and CD+A: chlorproguanil-
dapsone+artesunate), G6PD status (deficient: hemizygous males and homozygous females) and day of follow-up.
doi:10.1371/journal.pone.0004031.g001
Table 3. Mean fractional reduction (6SD) in PCV according to treatment group (AQ+SP: amodiaquine+sulphadoxine-
pyrimethamine; CD+A: chlorproguanil-dapsone+artesunate), G6PD status (deficient: hemizygous males and homozygous females)
and proportion of patients whose PCV fell below 20 and 25%.
Group n Fractional reduction (SD) No. with PCV below 20% (%)b No. with PCV below 25% (%)
CD+A G6PD (B) 322 14.4 (7.9) 7 (2.2) 71 (22.0)
CD+A G6PD (A-) 21 22.3 (11.8) 4 (19.0) 10 (47.6)
AQ+SP G6PD (B) 342 16.4 (9.3) 9 (2.6) 93 (27.2)
AQ+SP G6PD (A-) 17 15.1 (9.4) 1 (5.9) 4 (23.5)
p = 0.0001 p= 0.005 p= 0.05
bResults by gender: CD+A G6PD (B) 5 girls and 2 boys; CD+A G6PD, 4 boys; AQ+SP G6PD (B) 1 girl and 8 boys; AQ+SP G6PD (A-) 1 girl.
doi:10.1371/journal.pone.0004031.t003
G6PD and Antimalarial Drugs
PLoS ONE | www.plosone.org 4 December 2008 | Volume 3 | Issue 12 | e4031
Early Treatment Failures compared to CD+A treatment [1],
contributed to the need for a blood transfusion.
As mentioned in the methods, at the beginning of the trial 41
patients were allocated to CD alone; data from this arm were not
included in the efficacy analysis [1] nor are they included in the
present analysis. It is however worth mentioning that 2 patients in
this group, a G6PD (A-) hemizygous male and a non-deficient
male were transfused within 48 hrs.
Overall the risk of receiving a blood transfusion was about 7.6
times higher in G6PD (A-) patients, including heterozygous girls,
(95% CI 2.2 to 25.6) compared to G6PD (B) patients regardless of
the antimalarial treatment (Table 4). If we consider the risk in
relation to the drug administered, G6PD (A-) individuals treated
with CD+A had a Risk Ratio of 10.2 compared to G6PD (B)
individuals (95% CI 1.8 to 59.3), whereas G6PD (A-) individuals
treated with AQ+SP had a Risk Ratio of 5.6 (95% CI 1.0 to 32.7)
compared with G6PD (B) individuals treated with the same drug.
White Blood Cell analysis
The median WBC count was similar in the treatment groups at
recruitment and at each day of the follow-up, 7, 14, 21 and 28 (all
p.0.1; data not shown).
Discussion
Malaria is a major cause of anaemia in tropical areas. In this
study, conducted in a high transmission area, the haematocrit fell
during acute malaria. This initial reduction was independent of
the treatment received. Malaria causes anaemia through haemo-
lysis of parasitized erythrocytes, accelerated clearance of uninfect-
ed erythrocytes, impaired compensation for this loss by bone
marrow dyserythropoeisis and haemolysis due to oxidative stress
[12]. Haemolysis may be exacerbated by some antimalarial drug
treatment. In the present study, G6PD hemizygous and homozy-
gous Rwandan children with uncomplicated P. falciparum malaria
treated with CD+A experienced an estimated decline in
haematocrit of nearly 2% per day (equivalent to about 0.7 g/
dL) compared with 1% per day in patients who received AQ+SP,
regardless of G6PD status.
The significantly steeper decline in haematocrit in G6PD-deficient
children treated with CD+A is most likely to have resulted from the
use of sulphone dapsone and its metabolite hydroxylamine.
Artesunate may cause a temporary suppression of reticulocytosis
which does not translate into anaemia, but would not explain the
differential effect in G6PD-deficient subjects. Wootton et al., [13]
tested CD alone or in combination with different doses of artesunate.
Although the study was not powered to conduct a formal comparison
of safety between treatments, the safety profile of CD, including the
haematological effects, did not appear to be influenced by the
artesunate dose. General use of dapsone is limited because of adverse
haematological reactions, particularly in subjects with G6PD
deficiency. The life span of erythrocytes is reduced when the drug
is taken, to a degree related to the dose and length of exposure and is
more evident in persons with G6PD deficiency [7,8,14,15]. Although
haematological toxicity is normally dose-dependent, even at low daily
dosage can cause serious adverse events. For the treatment of leprosy
dapsone has been used at 1–2 mg/kg per day in children, but there is
limited experience (or not documented) in children under five and in
leprosy patients with G6PD deficiency. In our study 2.3–4.7 mg/kg
CD once daily for 3 days was associated with increased haemolysis
and a greater risk of transfusion in children with G6PD deficiency.
By the end of the 28 day follow-up the haematocrit of most
patients, with or without G6PD deficiency, recovered to normal
levels. Drug induced haemolysis is self-limiting in individuals with
G6PD deficiency because only older red cells are destroyed during
drug challenge as these are the cells which are most enzyme
deficient, whereas newly produced erythrocytes have nearly
normal levels of G6PD which enables them to resist drug-induced
destruction [8].
In total, 10 patients had severe post-treatment haemolysis
requiring blood transfusion and the risk of receiving a blood
transfusion was higher in subjects with G6PD deficiency recipients
of CD+A.
In this trial we recruited children with a PCV$21%; we
hospitalized and carefully monitored them for the whole adminis-
tration of the drug, transfusing blood when necessary. Under normal
conditions these children would have received the treatment at the
health centre or the drug would have been self-administered at home
with the consequent risk of life threatening haemolysis.
In heterozygous females, the degree of deficiency is determined
by the outcome of X-chromosomal inactivation and on average
they have less severe clinical manifestations, although some
develop severe acute haemolytic anaemia. In fact one heterozy-
gous subject in this trial needed a blood transfusion.
Table 4. Relative Risk (95% CI) of receiving a blood transfusion according to G6PD status following treatment with chlorproguanil-
dapsone+artesunate (CD+A) or amodiaquine+sulphadoxine-pyrimethamine (AQ+SP).
CD+A AQ+SP TOTAL
No. receiving blood transfusion
Normal 2c/299 3/321 5/620
Heterozygous girls 0/23 1/21 1/44
Homozygous girls 0/3 1/1 1/4
Hemizygous boys 3/18 0/16 3/34
Relative Risk
Normal 1 1 1
Hemizygous boys 24.9 (4.4, 139.8) Not Applicable 10.9 (2.7, 43.9)
Hemizygous boys+homozygous girls 21.4 (3.8, 120.9) 6.3 (0.7, 57.4) 13.1 (3.7, 46.6)
Hemizygous boys+homozygous and heterozygous girls 10.2 (1.8, 59.3) 5.6 (1.0, 32.7) 7.6 (2.2, 25.6)
cOne patient G6PD (B) was transfused at day 14 for a concomitant disease. Results excluding this case are: RR 49.8 (5.5, 455.5), RR 42.7 (4.6, 393.1) and RR 20.4 (2.2,
191.7), for hemizygous boys, hemizygous boys+homozygous girls, and hemizygous boys+homozygous girls+heterozygous girls, respectively.
doi:10.1371/journal.pone.0004031.t004
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In 2002, a randomised clinical trial in Kenya [16] found that
the degree of haemoglobin decline between days 0 and 7 was
greater in children treated with CD than with SP; 6.9% (13/188)
of children receiving CD developed severe anaemia (haemoglobin
levels of 5 g/dL or less) and exited the trial compared with 1.5%
(3/195) of children receiving SP. However no further analyses
were performed on the G6PD deficiency status of the children.
In 2004, results of a randomised multicentre trial in Africa
[10,17] showed that patients with G6PD deficiency were at greater
risk for anaemia after CD treatment (OR=2.5; p,0.001) than
after SP (OR=0.9; p= 0.94), whereas there were no differences
between patients without G6PD deficiency who were recipients of
CD or SP (OR=0.9; p = 0.62) . The risk for having a .4 g/dl
drop in haemoglobin concentration was at least doubled in
patients with G6PD deficiency after CD treatment (OR=3.2;
p = 0.02).
More recently, preliminary results of a multi-centre, double-
blind Phase III trial of CD co-formulated with artesunate vs.
artemether-lumefantrine [18], showed a significant reduction in
haemoglobin due to haemolytic anaemia in patients with G6PD
deficiency, with lowest levels of haemoglobin occurring seven days
after treatment. Fifteen patients, all in the CDA group and 13 of
whom with G6PD, had severe post-treatment haemolysis requiring
blood transfusion in the study.
The prevalence of G6PD deficiency in African populations
varies from 28.1% in southwest Nigeria to 22.5% in Congo,
15.7% in Mali, 13.0% in Uganda and 9.0–15.5% in Gabon [5]. In
our study population the allele frequency of the G6PD was about
10% in boys and 8% in girls. In a previous study conducted in
Rwanda [19] screening for G6PD deficiency using cord blood
samples showed a phenotypic frequency of 3.8%.
Pro-oxidant drugs, including antimalarial drugs associated with
haemolysis in G6PD-deficient individuals are used commonly in
malaria endemic areas. Screening for G6PD deficiency before
drug administration of potentially pro-oxidants drugs although
seldom available, is necessary.
Conclusions
Chlorproguanil-dapsone+artesunate in Rwanda had a poor
safety profile in G6PD deficient individuals most likely as a result
of dapsone induced haemolysis. This drug combination has also
been previously reported to have poor efficacy (70% Adequate
Clinical and Parasitological Response at day 28 PCR corrected
[1]). CD is a fixed-dose combination produced by GlaxoSmithK-
line under the brand name of LapdapTM. The co-formulated
combination with artesunate, Lapdap-plusTM, was under devel-
opment, but because it was associated with an increased risk of
anaemia GSK has stopped the further development of the
combination therapy and commenced a product recall process
at pharmacy level in Kenya for LapdapTM the only market with
recent sales of the product [20].
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